Sistema de Salut de Catalunya
Institut Català de la Salut
[Taieb J] Department of Gastroenterology and Gastrointestinal Oncology, CARPEM Comprehensive Cancer Center, Georges-Pompidou European Hospital, AP-HP, Université Paris-Cité, Paris, France. Centre de Recherche des Cordeliers, INSERM, CNRS, Université Paris-Cité, Sorbonne Université, USPC, Equipe Labellisée Ligue Nationale Contre le Cancer, SIRIC CARPEM, Paris, France. [Modest DP] Department of Hematology, Oncology and Cancer Immunology (CVK), Charité-Universitaetsmedizin, Berlin, Germany. German Cancer Consortium (DKTK), partner site Berlin, German Cancer Research Centre (DKFZ), Heidelberg, Germany. [Fakih M] City of Hope Comprehensive Cancer Center, Duarte, USA. [Ciardiello F] Università degli Studi della Campania Luigi Vanvitelli, Naples, Italy. [Van Cutsem E] University Hospitals Gasthuisberg and University of Leuven (KUL), Leuven, Belgium. [Elez E] Vall d’Hebron Hospital Universitari, Barcelona, Spain. Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. UVic-UCC, Barcelona, Spain
Vall d'Hebron Barcelona Hospital Campus
2025-09-16T07:31:42Z
2025-09-16T07:31:42Z
2025-09-09
Bevacizumab; Colorectal cancer; Depth of response
Bevacizumab; Cáncer colorrectal; Profundidad de respuesta
Bevacizumab; Càncer colorectal; Profunditat de resposta
Objectives: This post hoc analysis of the SUNLIGHT trial sought to assess the response to treatment with trifluridine/tipiracil (FTD/TPI) + bevacizumab and FTD/TPI in patients with refractory metastatic colorectal cancer using tumor shrinkage (TS), early TS (ETS), duration of TS (DTS) and depth of response (DpR) as response-related parameters. Methods: TS was defined as any decrease from baseline of the sum of the longest diameter of target lesions. TS at first assessment was specified as ETS. DpR was defined as the maximum percentage change from baseline of the sum of the longest diameters of target lesions. DTS was defined as the time from first TS to first increase in tumor size, progressive disease, or death. Results: In the FTD/TPI + bevacizumab group, 48 % had TS and 39 % had ETS. In the FTD/TPI group, 21 % had TS and 17 % had ETS. In patients achieving ETS, median DTS was prolonged with FTD/TPI + bevacizumab compared to FTD/TPI (3.8 versus 2.1 months; HR: 0.34 [95 % CI: 0.22, 0.53]; P < 0.0001). Magnitude of DpR was greater with FTD/TPI + bevacizumab than with FTD/TPI. Conclusion: The survival benefit of treatment with FTD/TPI + bevacizumab versus FTD/TPI is likely associated with the improvement of ETS and DpR.
This analysis was funded by Institut de Recherches Internationales, Servier, France.
Article
Published version
English
Metàstasi; Recte - Càncer - Tractament; Còlon - Càncer - Tractament; Quimioteràpia combinada; Avaluació de resultats (Assistència sanitària); ANALYTICAL, DIAGNOSTIC AND THERAPEUTIC TECHNIQUES, AND EQUIPMENT::Therapeutics::Therapeutics::Drug Therapy::Antineoplastic Protocols::Therapeutics::Drug Therapy::Antineoplastic Combined Chemotherapy Protocols; DISEASES::Neoplasms::Neoplasms by Site::Digestive System Neoplasms::Gastrointestinal Neoplasms::Intestinal Neoplasms::Colorectal Neoplasms; Other subheadings::Other subheadings::Other subheadings::/drug therapy; DISEASES::Neoplasms::Neoplastic Processes::Neoplasm Metastasis; ANALYTICAL, DIAGNOSTIC AND THERAPEUTIC TECHNIQUES, AND EQUIPMENT::Diagnosis::Prognosis::Treatment Outcome; TÉCNICAS Y EQUIPOS ANALÍTICOS, DIAGNÓSTICOS Y TERAPÉUTICOS::terapéutica::terapéutica::farmacoterapia::protocolos antineoplásicos::terapéutica::farmacoterapia::protocolos de quimioterapia antineoplásica combinada; ENFERMEDADES::neoplasias::neoplasias por localización::neoplasias del sistema digestivo::neoplasias gastrointestinales::neoplasias intestinales::neoplasias colorrectales; Otros calificadores::Otros calificadores::Otros calificadores::/farmacoterapia; ENFERMEDADES::neoplasias::procesos neoplásicos::metástasis neoplásica; TÉCNICAS Y EQUIPOS ANALÍTICOS, DIAGNÓSTICOS Y TERAPÉUTICOS::diagnóstico::pronóstico::resultado del tratamiento
Elsevier
European Journal of Cancer;227
https://doi.org/10.1016/j.ejca.2025.115644
Attribution 4.0 International
http://creativecommons.org/licenses/by/4.0/
Articles científics - HVH [3440]
